Bardoxolone (methyl) Size:Solid 2 mg p) increases GLT-1 expressions in

p) increases GLT-1 expressions in the hippocampus and ACC

InChi: InChI=1S/C49H78N6O10/c1-13-32(6)44(37(64-11)29-41(59)54-28-20-23-36(54)46(65-12)33(7)47(61)50-34(8)45(60)35-21-16-14-17-22-35)53(10)49(63)42(30(2)3)51-48(62)43(31(4)5)52(9)38(56)24-18-15-19-27-55-39(57)25-26-40(55)58/h14

(source: Eur J Cancer

PA-824 has potent in vitro activity against Mycobacterium tuberculosis

Bardoxolone (methyl) Size:Solid 2 mg p) increases GLT-1 expressions inBardoxolone methyl (also known as RTA 402 and CDDO methyl ester) is an orally available first in class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation. Bardoxolone methyl is currently being developed by Reata Pharmaceuticals, Inc. in partnership with Abbott